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SUMMARY Sunscreens are used to protect the skin from harmful 
effects of ultraviolet (UV) light but they do not completely prevent pho-
tocarcinogenesis, photoaging and photoimmunosuppression. They 
are useful for protection against UVB and short-wave UVA. Complete 
protection against long-wave UVA has not been achieved. There is no 
universally accepted method to evaluate UVA protection. Sun protec-
tion factor is a simple and internationally used method to compare 
sunscreen protection against UVB induced erythema. Adverse reac-
tions to sunscreens are not common but they should be considered 
especially in persons with pre-existing eczematous conditions or pho-
todermatoses. The use of sunscreens has increased steadily over 
the last decade; as a result, allergy and photoallergy to UV filters 
are now more frequent than in the past. Sensitization can occur from 
the various sunscreening agents and from the excipients included 
in formulations. An overview of sunscreens, their effectiveness, and 
adverse reactions is presented. 
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 INTRODUCTION
 The ultraviolet (UV) spectrum is divided into 
UVC (270 to 290 nm), UVB (290 to 320 nm), and 
UVA (320 to 400 nm). UVA is further subdivided 
into two regions: short-wave UVA or UVA II (320 to 
340 nm) and long-wave UVA or UVA I (340 to 400 
nm). An UVC ray does never reach the earth’s sur-
face. The atmosphere, especially the ozone layer, 
screens it out. UVA and UVB radiation reaches the 
earth’s surface in amounts determined by the time 
of year, time of day, latitude, altitude, ozone levels, 
cloud cover, and atmospheric particulate matter 
(1). The UVA to UVB ratio is approximately 20:1, 
and at least two thirds of this UVA is long-wave 
UVA I (2). UVB is greatest during the summer. 
UVA is much more constant through the year (3). 
About 80% of UVB and 70% of UVA radiation are 
present between 10.00 a.m. and 2:00 p.m. (3).
 UV radiation has acute and chronic effects 
on the skin. The epidermis mostly absorbs UVB. 
UVA penetrates more deeply into the skin, to the 
dermis. UV radiation generates reactive oxygen 
species (such as singlete oxygen, hydrogen per-
oxide and superoxide anion) that damage and de-
stroy the skin (4).  It is well documented that UV 
radiation causes sunburn, premature aging of the 
skin, skin cancers and cataracts, immunosuppres-
sion, and activation of latent viruses (5). Some of 
the acute and chronic effects of UV radiation are 
shown in Fig. 1 (6).
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 The measures that can be taken to achieve 
optimal sun protection include avoidance of sun 
exposure, use of photoprotective clothing, and ap-
plication of broad-spectrum sunscreens. In recent 
years, scientists around the world have been de-
veloping novel agents and experimental modali-
ties to minimize the harmful effects of UV radia-
tion, such as antioxidants, alpha-MSH, polyphenol 
in green teas, genistein, NF-kB decoy oligodeoxy-
nucleotides, pTpT vaccination and IL-12 (7).
 SUNSCREENS
 Sunscreens have become widely use for the 
prevention of short- and long-term sun damage. 
They are incorporated into a broader range of 
consumer products such as facial cosmetics, hair 
sprays and dyes, perfumes, shampoos, and shav-
ing creams (8). They are regulated as drugs in the 
USA, Canada and Australia, and as cosmetics in 
Europe.
 Mechanism of action 
 According to the mechanism of action, sun-
screens are divided into two broad categories: 
chemical (organic) sunscreens and physical (inor-
ganic) sunscreens or sunblockers.
 Chemical sunscreens are agents that absorb 
specific photons of UV radiation with excitation to 
a higher energy state. They are generally aromatic 
compounds conjugated with an electron-releasing 
group para or ortho to an electron-acceptor group. 
These chemical structures absorb the UV photons 
causing delocalization of electrons from the elec-
tron-releasing to the electron-acceptor and move 
the molecule to a higher energy state. Later, the 
molecule returns to its basal state while emitting 
the energy that is lower in magnitude than the en-
ergy initially absorbed to cause the excitation (9) 
(Fig. 2).
Figure 1. Acute and chronic skin  effects of UV ra-
diation (Self modification made after Jeanmougin 
M. Notions fondamentales de photobiologie cuta-
nee. In: Jeanmougin M. Photodermatoses et pho-
toprotection. Unite de Photobiologie Dermatolo-
que, Hospital Saint-Louis, Paris, 1983;11-39.(6))
 Chemical sunscreens are wavelength-selec-
tive with a specific absorption spectrum. Therefore, 
they are divided into UVB and UVA sunscreens. 
The UVB sunscreens are effective in absorbing 
the entire UVB spectrum. On the other hand, UVA 
sunscreens have a limited absorption spectrum, 
primarily absorbing shorter UVA II wavelengths 
(320-360 nm) (10).
 The chemical sunscreens used today and their 
ranges are as follows: UVB sunscreens including 
cinnamates (290-320 nm; λmax 311 nm), salicy-
lates (290-320 nm; λmax 307 nm), octocrylenes 
(290-320 nm; λmax 303 nm), enisilizoles (λmax 
310 nm), camphor derivatives (λmax 300 nm); 
UVA sunscreens including butyl methoxydiben-
zoylmethane (avobenzone; Parsol 1789, 305-385 
nm; λmax 358 nm), butyl tetraphthalydine dicam-
phor sulfonic acid (Mexoryl SX, λmax 345 nm); 
and UVA and UVB sunscreens including benzo-
phenones (250-365 nm; λmax 288 or 325 nm) and 
Figure 2.  Chemical and physical sunscreens and 
their absorbtion spectra. Modified from: DeBuys 
HV, Levy SB, Murray JC, Madley DL, Pinnell SR. 
Modern approaches to photoprotection. Derma-
tol Clin 2000;18:577-90 (4), and Braun-Falco O, 
Plewig G, Wolff HH, Burgdorf WH. Sunscreens. 
In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf 
WH, eds. Dermatology. 2nd ed. Berlin, Heidelberg: 
Springer-Verlag; 2000. p.1735-6. (11)
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menthyl anthranilates  (λmax 336 nm) (4,11).
 Physical sunscreens create a barrier that re-
flects, scatters, or physically blocks UV light. They 
have been defined as opaque formulations, the 
effectiveness of which depends on the diameter 
or size of their particles and the thickness of the 
film to reflect or scatter UV radiation and visible 
light (12). The newer micro-sized forms of physi-
cal blockers are not just inert materials; they may 
also function in part by absorption. Physical sun-
screens are categorized into chemicals that can 
scatter visible light and UV radiation equally well, 
scatter visible light and absorb UV radiation, or 
scatter and absorb visible light and UV radiation to 
a different extent (13). Titanium dioxide and zinc 
oxide in micro-sized forms can absorb UV as well 
as scatter and reflect visible light and UV radia-
tion (13). Titanium dioxide and zinc oxide protect 
against UV light from 250 to 340 nm, but protec-
tion against UVA1 is statistically superior for zinc 
oxide (340 to 380 nm) (14).
 Sun protection factor and UVA protection 
 methods
 Sun protection factor (SPF) is a laboratory-
derived effectiveness number of the sunscreen 
preparation. The concept of SPF was originally 
proposed by the Austrian scientist Franz Greiter 
(15). SPF is defined as the dose of UV radiation 
required to produce 1 minimal erythema dose 
(MED) on sunscreen-protected skin divided by the 
dose of UV radiation required to produce 1 MED 
on unprotected skin. Based on this definition, for 
example, an individual who burns after 20 minutes 
of sun exposure can extend the period of time until 
the burn begins at one hour with SPF 3.
 The proposed sunscreen evaluation guide-
lines include a detailed and very accurate protocol 
determined in a number of tested subjects, their 
skin type (types I, II, III according to Fitzpatrick), 
the site of testing (i.e. lower back), the source of 
light, and the method of reading the results and 
calculating the final SPF (9). The standard method 
of SPF testing involves a sunscreen application 
of 2 mg/cm2 with a gloved finger. Several recent 
studies have shown that most persons apply only 
20% to 60% of the amount of sunscreen (0.5-1.0 
mg/cm2) used to measure SPF, therefore the SPF 
measured in the laboratory may be as much as 
30% to 50% of the measurements obtained in 
sunlight (16,17). 
 The SPF is based on the measurements of 
photoprotection against erythema induced by UVB 
radiation. Higher SPF product allows individuals to 
spend greater amounts of time in the sun without 
burning and allowing exposure to the high doses 
of UVA. There is no exact protocol for testing UVA 
protection. The methods of UVA protection avail-
able are shown in Table 1 (4). In vivo methods 
include immediate pigment darkening, persistent 
pigment darkening, protection factor in UVA de-
termination, and erythema induced after topical 
psoralens application and UVA exposure (18-23). 
The critical wavelength determination is an in vi-
tro method for testing UVA protection (20,24). A 
detailed discussion is beyond the scope of this ar-
ticle. Each method has its own limitations and in-
dications for a particular clinical situation and skin 
type. The American Academy of Dermatology 
Consensus Conference on UVA Protection of 
Sunscreens recommends the critical wavelength 
method as a criterion for broad-spectrum claim. 
The threshold should be 370 nm (20). This method 
should be combined with an in vivo method (20).
Method Endpoint Indication
UVA protection factor (SPF) Erythema UV-A II
UVA protection factor Erythema UV-A II 
Skin phototypes I and II
Persistent pigment darkening Delayed pigment darkening Full UV-A
Skin phototypes III and IV
Phototoxic protection factor Erythema with topical photosensitizer Full UV-A photosensitivity
Photosensitivity disease study Flare in disease process Specific photosensitivity diseases
In vitro Transmittance through substrate (such 
as thin film)
Screening materials  
Convenient and practical
Table 1. UVA protection methods
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Vehicle
 The vehicle is significant for determining sun-
screen efficacy and cosmetic effect. It determines 
whether a sunscreen remains effective under gen-
eral use conditions such as swimming and sweat-
ing (10). Lotions and creams are the first choice for 
most individuals. Gels penetrate better and offer a 
more rapid protection but have a greater potential 
of irritation, especially in the eye region. Sticks are 
more difficult to apply but are useful for protection 
of limited areas such as lips, nose and around the 
eyes. Aerosols are cosmetically elegant and rap-
idly cover wide areas (4,11).
 Sunscreens are classified according to their 
resistance to water or waterproof qualities (10). A 
water-resistant product maintains the SPF level 
after 40 minutes of water immersion, whereas a 
very water-resistant or water-proof product should 
show the same SPF after 80 minutes of water im-
mersion (25).
Adverse reactions to sunscreens
 Adverse reactions to sunscreens are relative-
ly rare and include subjective (sensory) irritation, 
contact urticaria, contact dermatitis, both irritant 
and allergic as well as phototoxic and photoaller-
gic reactions.
 Subjective (sensory) irritation, cosmetic intol-
erance syndrome, or status cosmeticus (26) are 
the most frequently reported adverse reactions 
to sunscreens (27). The reactions are described 
as stinging, burning or itching without visible skin 
signs, occurring within 30 to 60 minutes of cutane-
ous exposure (28) and disappearing within 2 hours 
or sometimes a few of days of exposure (27). Such 
reactions can be explained as biochemical irrita-
tion in a sensitive skin (27). The reaction usually 
occurs on the face, especially around the eyes.
 Contact urticaria to sunscreens can be im-
mune (type I immediate hypersensitivity) or non-
immune (29). It is less common than contact der-
matitis (30). Individuals with contact urticaria to 
sun-screening products describe the sensation of 
burning, stinging, or itching with redness or urti-
caria shortly after application of the product. Vari-
ous methods have been used for testing patients 
for contact urticaria. For example, patch test to 
unaffected skin on the volar forearm for 15 to 20 
minutes, then observing the test site after 45 min-
utes (30).
 Contact and photocontact dermatitis, both 
allergic and irritant, can occur not only from the 
various sunscreening agents but also from the ex-
cipients such as emulsifiers, antioxidants and pre-
servatives included in the formulation (28). Some-
times a patient will react to series of chemically 
related compounds (para-amino compounds). The 
use of sun-barrier (benzophenone) is associated 
with the risk of contact or photocontact allergic re-
actions (8). Cross-reactions occur between aniline 
dyes, sulfonamides, benzocaines and quinones, 
and phenothiazines. Sometimes a substance may 
be metabolized in the body so that the altered 
structure may show an unexpected cross allergy. 
Because of their mechanism of action and in-
creasing use, chemical sunscreens have become 
one of the most common causes of photocontact 
dermatitis (31). PABA, oxybenzone, avobenzone 
and cinnamates are the most common senzitiz-
ers. During the ‘60ies, PABA was described as the 
leading cause of contact allergy among sunscreen-
ing agents (32). Its high sensitizing properties and 
carcinogenic potential (PABA can decompose to 
produce a nitrosamine degradation product) (33) 
were the causes for PABA being practically with-
drawn from sunscreening products, so today most 
products are claimed  as being “PABA-free”. PABA 
esters such as padimate O (octyl-dimethyl PABA) 
appear to be less sensitizing than PABA (28). Oxy-
benzone (benzophenone-3) has replaced PABA in 
sunscreening formulations, and it is the most com-
mon UV filter in cosmetics. Its increasing diffusion 
has led to oxybenzone to become the most com-
monly reported cause of sunscreen allergy today 
(34-38). The wider use of avobenzone (butylme-
thoxydibenzoylmethane or Parsol 1789) will prob-
ably cause a third “epidemic” of sunscreen allergy 
(39).
 Physical sunblockers are not senzitizing, so 
excipients in a physical sunscreen should be sus-
pected if such reactions occur (10).
 Individuals with pre-existing eczematous con-
ditions have a significant predisposition to develop 
sensitization because of their impaired cutaneous 
barrier (34).
 Some authors suggest that sunscreening 
compounds should be tested in all cases of con-
tact dermatitis in sunlight-exposed areas (40,41). 
Testing for sunscreen allergy includes patch, pho-
topatch and scratch testing with all the ingredients 
in sunscreen formulations (chemical sunscreens, 
physical sunscreens and excipients included in 
formulations) (42,43). Photopatch testing is per-
formed by applying nonirritating doses of poten-
tial photoallergens in duplicate sets on the intact 
skin of the back. One set is kept covered while the 
ACTA DERMATOVENEROLOGICA CROATICA
Pustišek et al:   Acta Dermatovenerol Croat
A review of suncreens and their adverse reactions   2005;13(1):28-35
32
other is exposed to 5-10 J/cm2 of UVA radiation 
24 hours later. The irradiated and nonirradiated 
sets are then compared 24 hours after light ex-
posure. The diagnosis of contact allergy is made 
when the nonirradiated and irradiated areas are 
positive. The diagnosis of photocontact allergy is 
made when only the irradiated set shows positive 
reaction. When both sites are positive but the ir-
radiated site shows stronger reaction than the 
nonirradiated site, contact allergy associated with 
photoallergy is diagnosed (43,44). The common 
allergic substances are chlorpromazine, musk 
ambrette, promethazine, benzophenone-3 and 
-10, PABA and octyl methoxycinnamate (Parsol 
MCX).
 Physical sunscreens may be so occlusive that 
they can cause miliaria (28). Acneiform eruption 
to sunscreen products is rare (42). Some authors 
report that sunscreens could affect vitamin D syn-
thesis causing measurable decreases in the syn-
thesis of vitamin D3. Another report shows that 
regular use of sunscreens can reduce the level of 
circulating 25-hydroxyvitamin D (45,46). Marks et 
al. (47) found no significant difference in vitamin D 
levels between the sunscreen and placebo treat-
ed groups. Similar findings were recorded in the 
American sunscreen study using sunscreens with 
SPF 29 for a 2-year period (46).
 Microfine zinc oxide (Z-Cote) is an effective 
transparent broad-spectrum photostable sunblock 
to attenuate UV radiation (UVR) including UVA1 
(14). Zinc oxide is essentially insoluble. After ap-
plication to intact and psoriatic skin, essentially 
unchanged serum zinc levels were measured 
(14). It is nonreactive, easy to formulate with other 
sunscreens, and can be readily used in daily care 
or in beach products including waterproof formula-
tions. 
 The long-term use of a topical UVA/UVB sun-
screen has been shown to contribute significantly 
to the prevention of photoaging and solar elasto-
sis, decreased collagen content, nonspecific der-
mal inflammatory infiltrate, basement membrane 
abnormalities, increased glycosaminoglycan de-
position, and epidermal thickening (48). The regu-
lar use of sunscreens (not only on the warmest 
days in summer) can significantly reduce cutane-
ous neoplasia by suppression of precancerous le-
sions (49).
 Sunscreens (chemical and physical) by care-
ful application of products at a surface density of 
2 mg/cm2 (SPF is conventionally determined) are 
effective in photoprotection (50). Diffey and Grice 
demonstrated that there was no statistically sig-
nificant difference between the amounts of sun-
screens applied by subjects of different skin types, 
yet there was a tendency for subjects with lower 
skin types to apply more sunscreen than those 
who burnt less easily (50). Several studies have 
suggested the lack of correlation between the 
sunscreen SPF and protection of the skin immune 
system, potentially allowing for greater damage to 
the skin by removing the natural protective ery-
themal response to sun exposure. Murine studies 
have demonstrated that sunscreens provide high-
er erythemal protection than the protection from 
the systemic or local cutaneous immune systems 
(51). Davenport et al. studied impairment of the 
epidermal alloantigen-presenting capacity due to 
UV radiation and the protection provided by six 
sunscreen creams in the human skin explant sys-
tem (51). They proved that the creams tested in 
the study provided protection beyond their in vitro 
SPF values, and that the SPF obtained was highly 
UV wavelength specific but poorly correlated with 
SPF values in vivo. Future studies will encompass 
protection provided at DNA and protein levels in 
the explant system (51).
 Sunscreen allergy is uncommon in the con-
tact dermatitis clinic in Singapore (52). Out of 61 
patients only 5 were found to have positive aller-
gic reactions to 2-ethylhexyl-p-methoxycinnamate 
(Parsol MCX), mexenone, and oxybenzene. The 
authors conclude that the incidence may rise in 
the near future (52). Based on the 7-year expe-
rience of photopatch testing with sunscreens in 
Sweden (355 consecutive patients), benzophe-
none-3 (Eusolex 4360) was for the first time iden-
tified as the most common allergen, followed by 
isopropyl dibenzoylmethane (Eusolex 8020) and 
butyl methoxydibenzoylmethane (Parsol 1789). 
The authors pointed to the importance of includ-
ing UV filters in the standard photopatch protocol 
(53). Zhang et al. report on erythema-multiforme-
like eruption that appeared 10 days after photo-
allergic contact dermatitis due to an oxybenzone 
sunscreen cream (Deepan®). The patient’s erup-
tion persisted for some 20 days despite treatment 
with topical and systemic corticosteroids (54).
 Photosensitive patients often comment that 
sunscreen products seem to be of little benefit. 
Azurdia et al. performed fluorescence measure-
ment (spectroscopy) on all uncovered body areas 
(17 sites) after applying sunscreen in a manner 
they would normally do on a bright sunny day. The 
overall median sunscreen thickness was 0.5 mg/
cm2 with median thickness at different sites rang-
ing from 0 to 1.2 mg/cm2. As the efficacy of pho-
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toprotection provided by a sunscreen depends on 
the amount applied, the SPF achieved in a clinical 
setting will be by far lower than the anticipated one, 
and photosensitive patients should be advised to 
use high SPF products (55). 
 Photocontact dermatitis due to sunscreens 
or other allergens is only rarely observed in chil-
dren. Hence, Ferriols and Boniche have described 
photoallergic eczema caused by a chemical sun-
screen in a 12-year-old girl, with cross-reactions 
to ketoprofen and oxybenzones (56). Using Eu-
ropean Colipe Guidelines, Gabard and Ademola 
demonstrated the minimal erythemal dose (MED) 
of the lower lip to be higher than the back skin 
MED in fair-skinned people (57). The lipstick sun-
screen effect measured on the lips was found to 
be lower than the one measured in the classic way 
on the skin of the back. This may be due to the 
adaptation of this particular anatomic location to 
continuous UVR exposure (57).
 UV exposure causes cataract formation, sun-
burn, premature aging of the skin, activation of 
latent viruses, and immune suppression, which 
contribute to the development of skin cancer. Ng-
hiem et al. suggest that sunlight may depress the 
protective effect of prior vaccination, and point to 
the need of UVA protection when designing sun 
protection strategies (58). UV exposure suppress-
es immune memory and elicitation of immune re-
sponse to a common opportunistic pathogen (58-
60).
 In recent years, novel agents and experimen-
tal modalities with the potential to offer enhanced 
protective effects against deleterious sequels of 
sun exposure have been elucidated, e.g., anti-
oxidants, alpha-MSH, polyphenol in green teas, 
genistein, NF-kB decoy oligodeoxynucleotides, 
pTpT vaccination, and IL-12 (61). As these new 
photo-protective tools are being developed by sci-
entists around the world, greater effort is needed 
to promote sun protection awareness in the gen-
eral public.
 CONCLUSION
 The use of sunscreens has increased steadily 
over the last decade as people become ever more 
aware of the harmful effects of UV radiation. The 
sunscreening ingredients have been incorporated 
in cosmetic products to prevent photoaging and 
the carcinogenic effect of solar radiation. As the re-
sult, allergy and photoallergy to UV filters are rela-
tively rare but more frequent than in the past. Sen-
sitization can develop to the various sunscreening 
agents and to the excipients in the formulations. 
It is concluded that sunscreening agents should 
be tested in all cases of contact dermatitis on the 
sunlight exposed areas, especially in patients with 
photodermatoses. It is important to note that us-
ing sunscreens does not allow for a prolonged sun 
exposure. Avoiding sun exposure, especially be-
tween 10.00 a.m. and 4:00 p.m., staying in shade, 
wearing protective clothing, broad hat and sun-
glasses, and regular use of broad-spectrum UVA 
and UVB sunscreens with at least SPF 15 remain 
the best and most desirable methods of sun pro-
tection. 
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